252 related articles for article (PubMed ID: 33917094)
1. BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia.
Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; R Payer Á; González-García E; López-Soto A; Gonzalez S
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917094
[TBL] [Abstract][Full Text] [Related]
2. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia.
Sordo-Bahamonde C; Lorenzo-Herrero S; Martínez-Pérez A; Gonzalez-Rodriguez AP; Payer ÁR; González-García E; Aguilar-García C; González-Rodríguez S; López-Soto A; García-Torre A; Gonzalez S
Cancer Immunol Immunother; 2023 Jul; 72(7):2529-2539. PubMed ID: 37041226
[TBL] [Abstract][Full Text] [Related]
3. LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.
Sordo-Bahamonde C; Lorenzo-Herrero S; González-Rodríguez AP; Payer ÁR; González-García E; López-Soto A; Gonzalez S
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925565
[TBL] [Abstract][Full Text] [Related]
4. Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.
Sordo-Bahamonde C; Lorenzo-Herrero S; Granda-Díaz R; Martínez-Pérez A; Aguilar-García C; Rodrigo JP; García-Pedrero JM; Gonzalez S
Mol Cancer; 2023 Aug; 22(1):142. PubMed ID: 37649037
[TBL] [Abstract][Full Text] [Related]
5. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
6. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
Sportoletti P; De Falco F; Del Papa B; Baldoni S; Guarente V; Marra A; Dorillo E; Rompietti C; Adamo FM; Ruggeri L; Di Ianni M; Rosati E
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206399
[TBL] [Abstract][Full Text] [Related]
7. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
[TBL] [Abstract][Full Text] [Related]
8. BTLA-HVEM Checkpoint Axis Regulates Hepatic Homeostasis and Inflammation in a ConA-Induced Hepatitis Model in Zebrafish.
Shi W; Shao T; Li JY; Fan DD; Lin AF; Xiang LX; Shao JZ
J Immunol; 2019 Nov; 203(9):2425-2442. PubMed ID: 31562209
[TBL] [Abstract][Full Text] [Related]
9. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
M'Hidi H; Thibult ML; Chetaille B; Rey F; Bouadallah R; Nicollas R; Olive D; Xerri L
Am J Clin Pathol; 2009 Oct; 132(4):589-96. PubMed ID: 19762537
[TBL] [Abstract][Full Text] [Related]
10. The BTLA-HVEM complex - The future of cancer immunotherapy.
Wojciechowicz K; Spodzieja M; Wardowska A
Eur J Med Chem; 2024 Mar; 268():116231. PubMed ID: 38387336
[TBL] [Abstract][Full Text] [Related]
11. B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis.
Vendel AC; Jaroszewski L; Linnik MD; Godzik A
Clin Pharmacol Ther; 2024 Jul; 116(1):247-256. PubMed ID: 38676311
[TBL] [Abstract][Full Text] [Related]
12. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
Front Immunol; 2018; 9():2917. PubMed ID: 30619281
[TBL] [Abstract][Full Text] [Related]
13. BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer.
Demerlé C; Gorvel L; Olive D
Front Oncol; 2021; 11():682007. PubMed ID: 34532285
[TBL] [Abstract][Full Text] [Related]
14. Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis.
Lan X; Li S; Gao H; Nanding A; Quan L; Yang C; Ding S; Xue Y
Onco Targets Ther; 2017; 10():919-926. PubMed ID: 28243127
[TBL] [Abstract][Full Text] [Related]
15. Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1
Del Rio ML; de Juan CY; Roncador G; Caleiras E; Álvarez-Esteban R; Pérez-Simón JA; Rodriguez-Barbosa JI
Front Immunol; 2023; 14():1113858. PubMed ID: 37033927
[TBL] [Abstract][Full Text] [Related]
16. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.
Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707
[TBL] [Abstract][Full Text] [Related]
17. Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia.
Karabon L; Partyka A; Jasek M; Lech-Maranda E; Grzybowska-Izydorczyk O; Bojarska-Junak A; Pawlak-Adamska E; Tomkiewicz A; Robak T; Rolinski J; Frydecka I
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):137-145. PubMed ID: 27933341
[TBL] [Abstract][Full Text] [Related]
18. Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice.
Aubert N; Brunel S; Olive D; Marodon G
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208480
[TBL] [Abstract][Full Text] [Related]
19. [Expression and Significance of BTLA and Its Ligand HVEM in Patients with Chronic Myelomonocytic Leukemia].
Li C; Geng SX; Li MM; Su F; Chen XM; Deng CX; Huang X; Lai PL; Weng JY; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):56-62. PubMed ID: 32027253
[TBL] [Abstract][Full Text] [Related]
20. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
